Saltar al contenido
Merck

Molecular Transducers of Human Skeletal Muscle Remodeling under Different Loading States.

Cell reports (2020-08-07)
Tanner Stokes, James A Timmons, Hannah Crossland, Thomas R Tripp, Kevin Murphy, Chris McGlory, Cameron J Mitchell, Sara Y Oikawa, Robert W Morton, Bethan E Phillips, Steven K Baker, Phillip J Atherton, Claes Wahlestedt, Stuart M Phillips
RESUMEN

Loading of skeletal muscle changes the tissue phenotype reflecting altered metabolic and functional demands. In humans, heterogeneous adaptation to loading complicates the identification of the underpinning molecular regulators. A within-person differential loading and analysis strategy reduces heterogeneity for changes in muscle mass by ∼40% and uses a genome-wide transcriptome method that models each mRNA from coding exons and 3' and 5' untranslated regions (UTRs). Our strategy detects ∼3-4 times more regulated genes than similarly sized studies, including substantial UTR-selective regulation undetected by other methods. We discover a core of 141 genes correlated to muscle growth, which we validate from newly analyzed independent samples (n = 100). Further validating these identified genes via RNAi in primary muscle cells, we demonstrate that members of the core genes were regulators of protein synthesis. Using proteome-constrained networks and pathway analysis reveals notable relationships with the molecular characteristics of human muscle aging and insulin sensitivity, as well as potential drug therapies.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Roche
cOmplete, Mini, conjunto de inhibidores de proteasas sin EDTA, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
Puromicina dihydrochloride from Streptomyces alboniger, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human MBNL1
Sigma-Aldrich
MISSION® esiRNA, targeting human NID2
Sigma-Aldrich
MISSION® esiRNA, targeting human FKBP1A
Sigma-Aldrich
MISSION® esiRNA, targeting human BCAT2